[1]黎桂玉,林基勇.莪术醇对肝细胞癌miR-629、miR-24、miR-130a、miR-17的影响[J].医学信息,2022,35(01):107-110.[doi:10.3969/j.issn.1006-1959.2022.01.025]
　LI Gui-yu,LIN Ji-yong.Effects of Curcumol on miR-629, miR-24, miR-130a and miR-17 in Hepatocellular Carcinoma[J].Medical Information,2022,35(01):107-110.[doi:10.3969/j.issn.1006-1959.2022.01.025]
点击复制

莪术醇对肝细胞癌miR-629、miR-24、miR-130a、miR-17的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年01期
页码:
107-110
栏目:
论著
出版日期:
2022-01-01

文章信息/Info

Title:
Effects of Curcumol on miR-629, miR-24, miR-130a and miR-17 in Hepatocellular Carcinoma
文章编号:
1006-1959（2022）01-0107-04
作者:
黎桂玉; 林基勇
（1.广西中医药大学基础医学院，广西 南宁 530200；2.深圳市中医院感染性疾病科，广东 深圳 518000）
Author(s):
LI Gui-yu; LIN Ji-yong
(1.School of Basic Medicine,Guangxi University of Chinese Medicine,Nanning 530200,Guangxi,China;2.Infectious Diseases Department, Shenzhen Traditional Chinese Medicine Hospital,Shenzhen,Guangdong,China)
关键词:
莪术醇; 肝癌; microRNAs
Keywords:
Curcumol; Liver cancer; microRNAs
分类号:
R259
DOI:
10.3969/j.issn.1006-1959.2022.01.025
文献标志码:
A
摘要:
目的 探讨莪术醇对肝癌miR-629、miR-24、miR-130a和miR-17表达的影响，从microRNAs角度揭示莪术醇抗肝癌的机制。方法 取人肝癌细胞株HepG2进行培养，待细胞生长良好，将其分为对照组、50 μg/ml莪术醇及100 μg/ml莪术醇药物组，每组3瓶。莪术醇（50、100 μg/ml，少量DMSO溶解）药物组换入含莪术醇的培养液作用，对照组予少量DMSO，作用于人肝癌细胞株HepG2。48 h后提取各组总RNA，实时荧光定量PCR检测莪术醇对miR-17、miR-130和miR-24、miR-629表达的调控作用。结果 两个莪术醇药物组中miR-130a-5P、miR-17-3P的表达水平均高于对照组，差异有统计学意义（P＜0.05）；两个莪术醇药物组中miR-629-3P、miR-24-1-3P表达水平均低于对照组，差异有统计学意义（P＜0.05）； 50 μg/ml莪术醇药物组的miR-17-3P表达水平高于100 μg/ml莪术醇药物组，差异有统计学意义（P＜0.05）；两个莪术醇药物组其余miRNAs表达水平比较，差异无统计学意义（P＞0.05）。结论 莪术醇可能通过上调miR-130a-5P、miR-17-3P，下调miR-629-3P、miR-24-1-3P的表达发挥抗肝癌作用。
Abstract:
Objective To investigate the effects of curcumol on the expression of miR-629, miR-24, miR-130a and miR-17 in liver cancer, and to reveal the mechanism of curcumol against liver cancer from the perspective of microRNAs.Methods Human hepatocellular carcinoma cell line HepG2 was cultured. When the cells grew well, they were divided into control group, 50 μg/ml curcumol group and 100 μg/ml curcumol group, with three bottles in each group. The curcumol (50 and 100 μg/ml, dissolved in a small amount of DMSO) drug group was replaced with the culture medium containing curcumol, and the control group was treated with a small amount of DMSO, acting on human liver cancer cell line HepG2. After 48 h, total RNA was extracted from each group, and the regulation of curcumol on the expression of miR-17, miR-130, miR-24 and miR-629 was detected by real-time quantitative PCR.Results The expression levels of miR-130a-5P and miR-17-3P in the two curcumol groups were higher than those in the control group, and the difference was statistically significant (P<0.05). The expression levels of miR-629-3P and miR-24-1-3P in the two curcumol groups were lower than those in the control group, and the difference was statistically significant (P<0.05). The expression level of miR-17-3P in the 50 μg/ml curcumol group was higher than that in the 100 μg/ml curcumol group, and the difference was statistically significant (P<0.05). There was no significant difference in the expression level of miRNAs between the two curcumol groups (P>0.05).Conclusion Curcumol may play an anti-HCC role by up-regulating miR-130a-5p and miR-17-3p and down-regulating the expression of miR-629-3p and miR-24-1-3p.

参考文献/References:

[1]Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249. [2]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[3]容敏华,葛莲英,余家华,等.2014-2019年广西城市癌症早诊早治项目肝癌筛查和随访结果分析[J].中国肿瘤,2021,30(5):328-333.[4]国家癌症中心.2019中国肿瘤登记年报[M].北京:人民卫生出版社,2021.[5]曹梦迪,王红,石菊芳,等.中国人群肝癌疾病负担：多数据源证据更新整合分析[J].中华流行病学杂志,2020,41(11):1848-1858.[6]郭芳,黎莉莉,臧林泉.莪术醇通过下调Bcl-2蛋白表达介导抗乳腺癌的机制研究[J].中国临床药理学杂志,2018,34(10):1175-1178.[7]黎莉莉,郭芳,莫斯喻,等.莪术醇诱导H1650肺癌细胞凋亡的机制探讨[J].沈阳药科大学学报,2019,36(2):175-179.[8]臧文华,郅琳,郭晓娟,等.莪术醇联合顺铂对人肝癌裸鼠原位移植瘤生长的抑制作用及对Bcl-2表达的影响[J].科学技术与工程,2018,18(24):220-224.[9]黎桂玉.莪术醇干预大鼠血瘀型肝纤维化及LSEC超微结构的实验研究[D].南宁:广西中医药大学,2017.[10]郑洋,梁天坚,王佳慧,等.莪术醇对肝窦内皮细胞MAPK信号通路作用的实验研究[J].中华中医药学刊,2021,39(1):57-61.[11]郑洋,卢能源,黄永贤,等.基于TGF-β1/Smad信号通路探讨莪术醇对肝纤维化小鼠作用的实验研究[J].中华中医药学刊,2021,39(1):1-11.[12]郑洋,王佳慧,梁天坚,等.莪术醇对肝星状细胞Rho-ROCK信号通路作用的实验研究[J].中国医院药学杂志,2019,39(15):1517-1520.[13]郑洋,王嘉孺,刘露露,等.基于Toll样受体4/核因子-κB信号通路研究莪术醇抗肝纤维化的分子机制[J].临床肝胆病杂志,2020,36(7):1508-1513.[14]Wen Y,Han J,Chen J,et al.Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma[J].Int J Cancer,2015,137(7):1679-1690.[15]Yerukala Sathipati S,Ho SY.Novel miRNA signature for predicting the stage of hepatocellular carcinoma[J].Sci Rep,2020,10(1):14452.[16]Sartorius K,Sartorius B,Winkler C,et al.The biological and diagnostic role of miRNA’s in hepatocellular carcinoma[J].Front Biosci (Landmark Ed),2018(23):1701-1720.[17]Qadir MI,Rizvi SZ.miRNA in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Approaches[J].Crit Rev Eukaryot Gene Expr,2017,27(4):355-361.[18]Elhefnawi M,Salah Z,Soliman B.The Promise of miRNA Replacement Therapy for Hepatocellular Carcinoma[J].Curr Gene Ther,2019,19(5):290-304.[19]Wang X,Gao J,Zhou B,et al.Identification of prognostic markers for hepatocellular carcinoma based on miRNA expression profiles[J].Life Sci,2019(232):116596.[20]Li D,Zhang J,Li J.Role of miRNA sponges in hepatocellular carcinoma[J].Clin Chim Acta,2020(500):10-19.[21]Nagy á,Lánczky A,Menyhárt O,et al.Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets[J].Sci Rep,2018,8(1):9227.[22]Wang R,Hu X,Liu X,et al.Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis[J].PLoS One,2021,16(4):e0249881.[23]贾冰.莪术醇、没食子酸配伍对人肝癌细胞SMMC-7721侵袭转移的影响及其机制研究[D].南京:南京中医药大学,2013.[24]林洁,黄炳臣,王娟,等.肝癌患者组织及血清微小RNA-24和微小RNA-629的表达水平及其临床意义[J].广西医学,2020,42(14):1775-1778.[25]周争光,汪蕊,李玉梅,等.mir-130a-3p及smad 4在肝细胞癌组织中的表达及临床意义[J].安徽医科大学学报,2017,52(3):383-387.[26]Asafo-Agyei KO,Samant H.Hepatocellular Carcinoma[M].In: StatPearls [Internet].Treasure Island (FL):StatPearls Publishing,2021.PMID: 32644603.[27]Murakami Y,Kawada N.MicroRNAs in hepatic pathophysiology[J].Hepatol Res,2017,47(1):60-69.[28]Hayes CN,Chayama K.MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma[J].Int J Mol Sci,2016,17(3):280.[29]Selitsky SR,Dinh TA,Toth CL,et al.Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs[J].mBio,2015,6(6):e01500-e01515.[30]查若鹏.肝癌转移相关microRNA的鉴定及其分子机制研究 [D].上海:复旦大学,2013.[31]Morishita A,Oura K,Tadokoro T,et al.MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review[J].Cancers,2021,13(3):514.[32]曹妮,孙建飞,魏海梁,等.miRNA对肝细胞癌微环境的调节作用[J].中西医结合肝病杂志,2021,31(1):90-93.[33]李振涛.miRNA-130a在肝癌组织中的表达[J].肿瘤基础与临床,2014,27(4):282-283.[34]王洁,杨建波,桂林,等.原发性肝癌诊断常用血清学标志物的研究进展[J].西南医科大学学报,2021,44(1):96-99.[35]任艳珍.莪术水煎液对人宫颈癌裸鼠移植瘤模型抗肿瘤作用的研究[D].太原:山西中医学院,2015.[36]唐德才,臧文华,冯海红.莪术不同品种含药血清对人胃癌细胞BGC823增殖、凋亡及核质比的影响 [J].北京中医药大学学报(中医临床版),2013,36(4):254-257,267,289.[37]李伟宏,田莉,刘俊保.莪术油对人子宫内膜癌HEC-1-B细胞增殖、凋亡及Caspase-3、Bax、Bcl-2蛋白表达的影响[J].河南中医,2021,41(3):384-387.[38]叶兴涛,史国军,陆宁,等.莪术提取物介导Wnt/β-catenin信号通路对人肝癌Hep-G2细胞的影响[J].解剖学杂志,2020,43(6):472-476.[39]杜林,陈德瑶,顾成娟,等.仝小林运用淫羊藿、莪术、三七治疗肝癌经验[J].吉林中医药,2021,41(1):16-18.[40]臧文华,胡久略,唐德才,等.黄芪、莪术联合顺铂对人肝癌裸鼠CD147、iNOS表达的影响[J].时珍国医国药,2020,31(4):785-788.[41]唐渊.莪术醇对肝癌、结肠癌的影响及机理研究[D].重庆:第三军医大学,2004.[42]黄岚珍,王娟,卢菲婷,等.莪术醇抑制人肝癌细胞HepG2增殖的机制[J].中国中药杂志,2013,38(11):1812-1815.[43]黄岚珍,杨飞城,阳晶,等.莪术醇诱导人肝癌HepG2细胞衰老及其机制研究[J].广西植物,2018,38(7):894-902.[44]吴皓,李政,彭信幸.莪术醇通过调控PI3K/AKT通路促进人肝癌HepG2细胞凋亡[J].中南药学,2019,17(1):11-14.[45]Shan SW,Fang L,Shatseva T,et al.Mature miR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN,GalNT7 and vimentin in different signal pathways[J].J Cell Sci,2013,126(Pt 6):1517-1530.[46]张雯雯,王宏光,陈明易,等.miR-130a在肝癌组织中的表达及对肝癌细胞迁移侵袭的影响[J].解放军医学院学报,2016,37(10):1090-1094.[47]Shincy JS,Panagal M,Jereena J,et al.Computational Identification of microRNA-17-3p in Breast Cancer Cells[J].Microrna,2017,6(3):208-212.

相似文献/References:

[1]修朋程,李 腾,李雅林,等.泰山山慈菇对小鼠肝癌的治疗作用及相关免疫机制研究[J].医学信息,2018,31(09):8.[doi:10.3969/j.issn.1006-1959.2018.09.003]
　XIU Peng-cheng,LI Teng,LI Ya-lin,et al.Study on the Therapeutic Effect and Mechanism of Taishan Mountain Mushroom on Liver Cancer in Mice[J].Medical Information,2018,31(01):8.[doi:10.3969/j.issn.1006-1959.2018.09.003]
[2]崔康健,杜成友.肝动脉化疗栓塞联合射频消融治疗肝癌的研究进展[J].医学信息,2018,31(09):16.[doi:10.3969/j.issn.1006-1959.2018.09.005]
　CUI Kang-jian,DU Cheng-you.Research Progress of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation for Liver Cancer[J].Medical Information,2018,31(01):16.[doi:10.3969/j.issn.1006-1959.2018.09.005]
[3]田 明,常伟平.UbcH10在肝癌中的表达及其与预后的关系[J].医学信息,2019,32(12):77.[doi:10.3969/j.issn.1006-1959.2019.12.024]
　IAN Ming,CHANG Wei-ping.Expression of UbcH10 in Hepatocellular Carcinoma and Its Relationship with Prognosis[J].Medical Information,2019,32(01):77.[doi:10.3969/j.issn.1006-1959.2019.12.024]
[4]许 吉.基于知识图谱和专利地图的我国抗肝癌药物研发态势研究[J].医学信息,2018,31(21):19.[doi:10.3969/j.issn.1006-1959.2018.21.007]
　XU Ji.Research and Development Situation of Anti-liver Cancer Drugs in China Based on Knowledge Map and Patent Map[J].Medical Information,2018,31(01):19.[doi:10.3969/j.issn.1006-1959.2018.21.007]
[5]兰福全,李秀云,卢 斌.四种肿瘤标志物对肝癌诊断的临床意义[J].医学信息,2018,31(21):164.[doi:10.3969/j.issn.1006-1959.2018.21.048]
　LAN Fu-quan,LI Xiu-yun,LU Bin.The Clinical Significance of Four Tumor Markers in the Diagnosis of Liver Cancer[J].Medical Information,2018,31(01):164.[doi:10.3969/j.issn.1006-1959.2018.21.048]
[6]李 闯,叶劲松,刘 昕,等.ZBP-89与缺氧信号因子HIF-1α在肝癌细胞中的 相关性研究[J].医学信息,2019,32(15):74.[doi:10.3969/j.issn.1006-1959.2019.15.023]
　LI Chuang,YE Jin-song,LIU Xin,et al.Correlation between ZBP-89 and Hypoxia Signaling Factor HIF-1α in Hepatoma Cells[J].Medical Information,2019,32(01):74.[doi:10.3969/j.issn.1006-1959.2019.15.023]
[7]赵瑶瑶,高 川,胡佳杰.循环miRNA监测肝细癌的研究[J].医学信息,2019,32(08):48.[doi:10.3969/j.issn.1006-1959.2019.08.016]
　ZHAO Yao-yao,GAO Chuan,HU Jia-jie.Research on the Study of Circulating miRNA for Monitoring Hepatocellular Carcinoma[J].Medical Information,2019,32(01):48.[doi:10.3969/j.issn.1006-1959.2019.08.016]
[8]孙 逊.性化护理对肝癌患者CT引导下射频消融术后 负性情绪及生活质量的影响[J].医学信息,2019,32(17):187.[doi:10.3969/j.issn.1006-1959.2019.17.065]
　SUN Xun.Effect of Humanized Nursing on Negative Emotion and Quality of Life after CT-guided Radiofrequency Ablation in Patients with Liver Cancer[J].Medical Information,2019,32(01):187.[doi:10.3969/j.issn.1006-1959.2019.17.065]
[9]徐 蓓,魏霞丽,常艳琴.肝癌患者术后自我饮食管理体验的质性研究[J].医学信息,2019,32(20):180.[doi:10.3969/j.issn.1006-1959.2019.20.058]
　XU Bei,WEI Xia-li,CHANG Yan-qin.Qualitative Study of Postoperative Self-Catering Management Experience in Patients with Liver Cancer[J].Medical Information,2019,32(01):180.[doi:10.3969/j.issn.1006-1959.2019.20.058]
[10]刘申颖,施彦卿,梅鹏飞,等.超声引导下经皮无水乙醇注射联合射频消融治疗中晚期肝癌的效果[J].医学信息,2019,32(22):87.[doi:10.3969/j.issn.1006-1959.2019.22.026]
　LIU Shen-ying,SHI Yan-qing,MEI Peng-fei,et al.Ultrasound-guided Percutaneous Ethanol Injection Combined with Radiofrequency Ablation for Advanced Hepatocellular Carcinoma[J].Medical Information,2019,32(01):87.[doi:10.3969/j.issn.1006-1959.2019.22.026]

更新日期/Last Update: 1900-01-01